# Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

> **NCT05179057** · PHASE3 · TERMINATED · sponsor: **AlloVir** · enrollment: 57 (actual)

## Conditions studied

- Adenovirus Infection

## Interventions

- **DRUG:** Posoleucel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05179057
- **Lead sponsor:** AlloVir
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-26
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Study discontinued as DSMB determined it was futile. No safety concerns were noted.
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05179057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05179057, "Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05179057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*